BC Innovations | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Hepatic; renal

INDICATION: Liver disease; renal damage Cell culture and mouse studies suggest inhibiting ACMSD could help prevent non-alcoholic fatty liver disease (NAFLD) and acute kidney injury (AKI). In mouse primary hepatocytes, the ACMSD inhibitor TES-991 decreased...
BC Extra | Oct 25, 2018
Preclinical News

Inhibiting metabolic enzyme to prevent NAFLD, acute kidney injury

TES Pharma s.r.l. (Perugia, Italy) is developing small molecule inhibitors of a metabolic enzyme that limits NAD+ production after the metabolic and cancer company and the Swiss Federal Institute of Technology Lausanne (EPFL) showed a...
Items per page:
1 - 3 of 3